Search: onr:"swepub:oai:DiVA.org:liu-88576" >
Cost-effectiveness ...
Cost-effectiveness of resuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
-
- Gandhi, Sanya K. (author)
- AstraZeneca LP, Wilmington, DE, USA
-
- Jensen, Marie M. (author)
- AstraZeneca, Lund, Sweden
-
- Fox, Kathleen M. (author)
- Strategic HealthCare Solution, Monkton, MD, USA
-
show more...
-
- Smolen, Lee (author)
- Medical Decision Modeling Inc, Indianapolis, IN, USA
-
- Olsson, Anders (author)
- Östergötlands Läns Landsting,Linköpings universitet,Internmedicin,Hälsouniversitetet,Endokrinmedicinska kliniken
-
- Paulsson, Thomas (author)
- AstraZeneca, Södertälje, Sweden
-
show less...
-
(creator_code:org_t)
- Dove Medical Press, 2012
- 2012
- English.
-
In: ClinicoEconomics and Outcomes Research. - : Dove Medical Press. - 1178-6981. ; 4, s. 1-11
- Related links:
-
https://liu.diva-por... (primary) (Raw object)
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.2...
-
show less...
Abstract
Subject headings
Close
- Background: To assess the long-term cost-effectiveness of rosuvastatin therapy compared with generic simvastatin and generic atorvastatin in reducing the incidence of cardiovascular events and mortality in a Swedish population with Framingham risk ≥20%.Methods: A probabilistic Monte Carlo simulation model based on data from JUPITER (the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) was used to estimate the long-term cost-effectiveness of rosuvastatin 20 mg daily versus simvastatin or atorvastatin 40 mg for the prevention of cardiovascular death and morbidity. The three-stage model included cardiovascular event prevention simulating the 4 years of JUPITER, initial prevention beyond the trial, and subsequent cardiovascular event prevention. A Swedish health care payer perspective (direct costs only) was modeled for a lifetime horizon, with 2008/2009 as the costing period. Univariate and probabilistic sensitivity analyses were performed.Results: The incremental cost per quality-adjusted life-year (QALY) gained with rosuvastatin 20 mg over simvastatin or atorvastatin 40 mg ranged from SEK88,113 (rosuvastatin 20 mg versus simvastatin 40 mg; Framingham risk ≥30%; net avoidance of 34 events/1000 patients) to SEK497,542 (versus atorvastatin 40 mg: Framingham risk ≥20%; net avoidance of 11 events/1000 patients) over a lifetime horizon. Probabilistic sensitivity analyses indicated that at a willingness-to-pay threshold of SEK500,000/QALY, rosuvastatin 20 mg would be cost-effective for approximately 75%–85% of simulations relative to atorvastatin or simvastatin 40 mg. Sensitivity analyses indicated the findings to be robust.Conclusion: Rosuvastatin 20 mg is cost-effective over a lifetime horizon compared with generic simvastatin or atorvastatin 40 mg in patients at high cardiovascular risk in Sweden.
Keyword
- cardiovascular disease
- cost-benefit analysis
- cost-effectiveness
- rosuvastatin
- simvastatin
- atorvastatin
- generic
- high risk
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database